

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Brii Biosciences Limited**  
**騰盛博药生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2137)**

**CLARIFICATION ANNOUNCEMENT**

Reference is made to the announcement of Brii Biosciences Limited (the “**Company**”) dated April 12, 2023 (the “**Announcement**”) in relation to, among others, (i) the grant (the “**Option Grants**”) by the Company of an aggregate of 3,281,000 share options (the “**Options**”) to certain employees of the Company and its subsidiaries (the “**Group**”) to subscribe for a total of 3,281,000 shares of par value US\$0.000005 each in the share capital of the Company (the “**Shares**”) in accordance with the terms of the post-IPO share option scheme adopted by the Company on June 22, 2021 (the “**Post-IPO Share Option Scheme**”) and (ii) the grant (the “**RSU Grants**”) by the Company of an aggregate of 870,500 restricted share units to certain employees of the Group in accordance with the terms of the post-IPO share award scheme adopted by the Company on June 22, 2021.

The board of directors of the Company (the “**Board**”) would like to clarify that there was an inadvertent clerical error on page 9 of the Announcement, and that the number of Shares underlying the Options that will be available for future grant pursuant to the Post-IPO Share Option Scheme after the Options Grants and the RSU Grants as disclosed in the Announcement should be “27,870,567 Shares”, instead of “28,698,567 Shares”. Save for this inadvertent clerical error, all other information and contents of the Announcement remain unchanged.

By order of the Board  
**Brii Biosciences Limited**  
**Dr. Zhi Hong**  
*Chairman*

Hong Kong, April 19, 2023

*As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.*